EUCTR2007-006475-36-GB进行中（未招募）1 期
Phase ll Study of the Adjunctive Use of Azacitidine in Patients Undergoing Reduced Intensity Allogeneic Transplantation for Acute Myeloid Leukaemia - RICAZA
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients >18 years and in whom allogeneic transplantation using a myeloablative conditioning regimen is contra-indicated.
- •1) Diagnosis
- •Patients who fulfil WHO criteria for AML
- •2) Patients with a HLA identical sibling or suitable matched unrelated donor. Suitable match equals no greater than a single allele mismatch and considered fit for reduced intensity transplant.
- •3) Give written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
- •4) Be willing and able to comply with the protocol for the duration of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria:
- •1) Patients with contraindications to receiving transplant conditioning therapy or Azacitidine.
- •2) Pregnant or lactating women or adults of reproductive potential not willing to use appropriate medically approved contraception during the trial and for 12 months post study.
- •3) Any co-morbidity that in the investigators opinion will affect the patients participation in this study.
研究者
相似试验
进行中（未招募）
不适用
A phase II study of the use of azacitidine for the treatment of patients with chronic graft-versus-host-disease who have failed treatment with corticosteroidsChronic Graft versus Host DiseaseMedDRA version: 18.1Level: PTClassification code 10066261Term: Chronic graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2014-005659-19-GBniversity of Birmingham
进行中（未招募）
1 期
ordic multicenter phase II study: Treatment of patients with Acute Myeloid Leukemia (AML) with AZACITIDINE and reduced dose of VENETOCLAX (including laboratory research for improvement of AML treatment).Acute myeloid leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2020-005461-14-DKRigshospitalet117
进行中（未招募）
1 期
ordic multicenter phase II study: Treatment of patients with Acute Myeloid Leukemia (AML) with AZACITIDINE and reduced dose of VENETOCLAX (including laboratory research for improvement of AML treatment).Acute myeloid leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2020-005461-14-FIRigshospitalet117
终止
1 期
Oral Azacitidine, Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple MyelomaMultiple MyelomaACTRN12613000283774The Alfred Hospital30
已完成
2 期
Adjunctive use of azacitidine in patients with acute myeloid leukaemia (AML) or myelodysplasia (MDS) undergoing a reduced intensity conditioned allogeneic transplantAcute myeloid leukaemia (AML) or myelodysplasia (MDS)CancerISRCTN36825171niversity of Birmingham (UK)37